Introduction {#s0001}
============

Diabetes is a major global public health concern. Its prevalence is increasing worldwide, having more than doubled in the past 20 years.[@cit0001] The International Diabetes Federation estimated that 1 in 11 adults or 415 million people worldwide were living with diabetes in 2015, with this figure predicted to increase to 642 million by 2040.[@cit0002] In patients with diabetes, influenza infection is associated with an increased risk of complications, including hospitalization and death.[@cit0003] Annual vaccination against seasonal influenza is therefore recommended by public health authorities worldwide for this high-risk group.[@cit0006] To ensure an efficient vaccination against influenza in vulnerable populations, the World Health Organization recommends a coverage rate of at least 75% in vulnerable populations. [@cit0009] However, recent data suggest that seasonal influenza vaccination uptake remains suboptimal in patients with diabetes in most countries.[@cit0010] One possible explanation for this finding may be lack of awareness of associated complications induced by influenza in this vulnerable group and possibly expected reduced vaccine performance due to immune dysfunction in patients with diabetes mellitus.[@cit0010]

Focusing on more severe forms of infections and associated complications, previous systematic reviews reported that all-cause hospitalization, hospitalization due to influenza or pneumonia during influenza season, and all-cause mortality were reduced in elderly diabetic patients following seasonal influenza vaccination.[@cit0013]^,^[@cit0014] In working-age diabetic patients, vaccination was associated with reductions in all-cause hospitalization and hospitalization for influenza and pneumonia; however, no direct effects on mortality were observed. Both reviews reported that the strength of available evidence was low to very low for all outcomes and residual confounding was present in most of the included studies published until January 2015. The current systematic review was undertaken to update and expand on these previous findings with the aim to provide a critical appraisal and summary of currently available data concerning the immunogenicity, safety, efficacy, effectiveness, quality of life and cost effectiveness of seasonal influenza vaccination in patients with diabetes.

Methods {#s0002}
=======

A systematic literature review was conducted following Cochrane guidelines[@cit0015] and Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines.[@cit0016]

Search strategy {#s0002-0001}
---------------

References for this systematic review were identified through searches in the PubMed, Embase and Cochrane Library databases from 1 January 2000 to 6 March 2017. Search strings were developed combining terms for influenza, vaccination and metabolic disorders, including diabetes mellitus. To be as extensive as possible and to collect all articles on any type of diabetes mellitus a broader search strategy on metabolic disorders was employed. In addition, various websites and data sources were searched for grey literature and the reference lists of included systematic reviews and meta-analyses were screened for additional relevant articles. The complete search strategy is shown in Appendix 1.

Inclusion and exclusion criteria {#s0002-0002}
--------------------------------

The three databases were searched for publications on diabetic patients vaccinated against seasonal influenza. Randomized controlled trials and observational studies on the immunogenicity, safety and efficacy of seasonal influenza vaccination in patients with type 1 and type 2 diabetes of any age were included. Furthermore, prospective and retrospective observational studies on effectiveness, quality of life and/or cost effectiveness of seasonal influenza vaccination in patients with type 1 and type 2 diabetes of any age were included. No language limits were applied.

The following articles were excluded: (i) studies not describing diabetic mellitus patients or describing mixed patient groups with chronic diseases (unless the diabetic group was analyzed separately); (ii) studies in which patients received the 2009 H1N1 pandemic influenza vaccine; (iii) letters to the editor, editorials, case reports or comments; and (iv) studies of insufficient methodological quality (as outlined below).

Study selection and critical appraisal {#s0002-0003}
--------------------------------------

Articles were selected by a three-step selection procedure based on (i) screening of title and abstract, (ii) screening of full-text article, and (iii) screening during the data-extraction phase. Titles and abstracts from the database searches were independently screened by two researchers. Selected references from the two researchers were included for full text selection. The first 10% of the full text articles was critically appraised by both researchers, for the remaining articles any doubts were discussed in detail. In case of discrepancy or disagreements during the selection phase, a third researcher was consulted. The study was discussed until consensus was reached. If more than one article reported on the same study, only the most relevant or complete article was included. Both articles were included if they provided relevant complementary data. The methodological quality of included studies was critically appraised using the methodology checklists from the Scottish Intercollegiate Guidelines Network (SIGN), which are applicable for different study designs.[@cit0017] Studies were critically appraised with a set of criteria that might have a significant effect on the risk of bias in the results reported and conclusions drawn. According to the number of risks assessed and the predicted effects on the results and conclusions, studies were classified as high, acceptable or low quality.[@cit0017]

The process of selection was registered in an Endnote library.

Data extraction {#s0002-0004}
---------------

Data from included articles were extracted into pre-defined evidence tables by one researcher and reviewed by the second researcher. Information was recorded on study characteristics (i.e. country, study design, influenza season, follow-up period and setting); study population (i.e. inclusion and exclusion criteria, gender, age and case definition); study results and critical appraisal. Depending on the objectives of the included studies, study results included data on the immune response, safety, efficacy, effectiveness, quality of life and cost effectiveness of seasonal influenza vaccination. Data from the evidence tables were used to construct summary tables per objective.

Definitions {#s0002-0005}
-----------

The immunogenicity of the influenza vaccine is most often measured in terms of hemagglutination inhibition (HI) titers, with the following parameters commonly derived in clinical trials: (1) geometric mean titer (GMT); (2) seroconversion rate (SCR); (3) seroprotection rate (SPR). SCR is usually defined as either a pre-vaccination HI titer \<1:10 and a post vaccination HI titer \>1:40 or a pre-vaccination HI titer ≥1:10 and a minimum four-fold rise in post-vaccination HI antibody titer. SPR is defined as the percentage of participants who attain reciprocal HI titers of ≥1:40. Predefined criteria for licensure in terms of SCR and SPR were in place at the time that most of the studies included in this review were conducted, although they are no longer considered as part of the licensure process. In the USA, the criteria for adults \<65 years of age and children were that the lower limit of the two-sided 95% confidence interval (CI) of the SCR should be ≥40%, and the lower limit of the 95% CI for the SPR should be ≥70%. (CBER[@cit0018] For adults ≥65 years of age, corresponding values were ≥30% and ≥60%. In Europe, the criteria were that the point estimates of the SCR and SPR should be ≥40% and ≥70%, respectively, in adults 18−60 years of age, and ≥30% and ≥60%, respectively, in adults \>60 years of age.[@cit0019]

Vaccine efficacy is commonly defined as the direct effect of a vaccine measured in pre-licensure randomized clinical trials, where vaccination occurs under optimal and controlled conditions. It is measured as the proportionate reduction in disease attack rate among vaccinated individuals compared with unvaccinated individuals.[@cit0020] Vaccine effectiveness is a "real world" measure of how well the seasonal influenza vaccine prevents influenza disease in the general population during a given influenza season, and is commonly assessed by observational post-licensure studies.[@cit0020]^,^[@cit0021] Reactogenicity, which is part of the safety profile assessment of a given vaccine, refers to the potential for expected and unexpected local or systemic adverse reactions following vaccine administration.

Results {#s0003}
=======

Study selection process {#s0003-0001}
-----------------------

The study selection process is summarized in [Fig. 1](#f0001){ref-type="fig"}. The search yielded 2,393 unique hits, from which 75 publications were considered eligible to be screened in full. In all, 15 studies met the criteria for inclusion in this systematic review. Figure 1.Flow chart summarizing the systematic literature search and study selection process.

Study characteristics {#s0003-0002}
---------------------

Key characteristics of the included studies are shown in [Table 1](#t0001){ref-type="table"}. The 15 studies included 2 randomized double-blind trials, 3 non-randomized clinical studies, 1 prospective cohort study, 7 retrospective cohort studies, and 2 case-control studies. The studies were performed over various influenza seasons during the period from 1992--2013 in Canada, Israel, Italy, Korea, the Netherlands, Spain, Taiwan, the UK and the USA. Very limited details were reported on the seasonal influenza vaccines; in seven studies a trivalent influenza vaccine was used (of which three specified the strains), in one article a subunit and virosomal vaccine were studied, and the other studies did not specify the influenza vaccine. Sample sizes ranged from 8 to 124,503 included diabetic patients. Six studies provided data on immunogenicity, two on safety, nine on vaccine effectiveness, and one on cost effectiveness. No studies providing data on vaccine efficacy or quality of life were identified. The main limitations or risks of study bias identified were the lack of descriptions of sample size calculations, significant differences in patient and clinical characteristics between study groups at baseline, potential variation in the application of diagnostic codes, the lack of influenza-specific outcomes and retrospective design. Seven studies were considered to be of acceptable quality and eight were considered to be of lower quality, according to the methodology checklists from Scottish Intercollegiate Guidelines Network (SIGN).[@cit0017] Table 1.Key characteristics of included studies and results of bias risk assessment.ReferenceCountryStudy designInfluenza seasonMean (SD) age[^a^](#t1fn0001){ref-type="fn"} in yearsGender, % male[^a^](#t1fn0001){ref-type="fn"}N[^a^](#t1fn0001){ref-type="fn"}Diabetes typePotential bias identified & expected impact***Immunogenicity*** [@cit0022]USANon-randomized clinical study2011-2012Young:[^b^](#t1fn0002){ref-type="fn"}50 (3)/42 (2)Young:42.9/27.0Young: 14/37Type 2- Low quality      Elderly: 8/28 + Non-diabetic age-matched control groups    Elderly:[^b^](#t1fn0002){ref-type="fn"}64 (2)/66 (1)Elderly: 50.0/35.7  - Small sample size; no sample size calculations; limited case definition; two different influenza vaccines were used         [@cit0023]CanadaNon-randomized clinical study2010-2012[^c^](#t1fn0003){ref-type="fn"}74.6 (6.5)/75.7 (6.6)NR102/119Type 2- Low quality        + Non-diabetic control group        - Small sample size; no sample size calculations; limited information on setting and case enrolment; differences at baseline[@cit0025]USAProspective cohort study2009-2011≥18[^d^](#t1fn0004){ref-type="fn"}2009: 34.7[^e^](#t1fn0005){ref-type="fn"}2009: 91/461Type 2+ Acceptable quality     2010: 39.3[^e^](#t1fn0005){ref-type="fn"}2010: 102/463 + Non-diabetic control group        - No sample size calculations; differences at baseline[@cit0026]USARandomized, double-blind trial2008-201014.3 (6.6)70.634Type 1- Low quality        - Small sample size, no sample size calculations, limited information on setting and enrolment        - Primary study objective was to assess the effect of abatacept on immunogenicity of vaccines in patients with type 1 diabetes; no non-diabetic control group***Immunogenicity and safety***[@cit0024]KoreaNon-randomized clinical study2012--201363.0 (9.7)/60.0 (14.1)48.6/29.2105/108Type 2- Low quality        + Non-diabetic control group        - Small sample size; limited case definition; differences at baseline[@cit0027]Italy Randomized, double-blind trial2007-200815.8 (5.3)/16.2 (3.5)[^f^](#t1fn0006){ref-type="fn"}  49.1/51.9[^f^](#t1fn0006){ref-type="fn"}53/52[^f^](#t1fn0006){ref-type="fn"}Type 1+ Acceptable quality        - Small sample size; no sample size calculations           - Comparative study of two different seasonal influenza vaccines; no non-diabetic control group   ***Effectiveness***     [@cit0036]UKRetrospective cohort study2003--201066.2 (13.3)/56.2 (16.3)[^g^](#t1fn0007){ref-type="fn"}53.9/54.2[^g^](#t1fn0007){ref-type="fn"}124,503[^h^](#t1fn0008){ref-type="fn"}Type 2+ Acceptable quality           + Unvaccinated diabetic control group           - No sample size calculations; differences at baseline; diagnostics code; no information on influenza seasons   [@cit0033]SpainRetrospective cohort study2002-200575.2 (6.5)/73.1 (6.9)42.2/39.81,586/1,064Type 1 & 2[^i^](#t1fn0009){ref-type="fn"}- Low quality           + Unvaccinated diabetic control group           - No sample size calculations; differences at baseline; no description of diabetes types; incomplete data; diagnostic codes; no influenza-specific outcomes   [@cit0030]IsraelRetrospective cohort study2000-200172.8 (0.6)/73.1 (0.5)[^j^](#t1fn0010){ref-type="fn"}51.8/42.1[^j^](#t1fn0010){ref-type="fn"}\
46.6/40.4 [^j^](#t1fn0010){ref-type="fn"}15,556/69,097Type 1 & 2[^i^](#t1fn0009){ref-type="fn"}- Low quality       74.7 (0.8)/74.2 (0.5)[^j^](#t1fn0010){ref-type="fn"}               - No sample size calculations; retrospective design; no description of diabetes types; diagnostic codes; limited information on exposure assessment; univariate analysis; no influenza-specific outcomes; no information on influenza season   [@cit0032]The NetherlandsNested case-control study1999-200068.1 (13.7)/69.8 (12.6)[^k^](#t1fn0011){ref-type="fn"}51.6/38.3[^k^](#t1fn0011){ref-type="fn"}192/1,561[^k^](#t1fn0011){ref-type="fn"}Type 1 & 2 (\>90% Type 2)+ Acceptable quality           - No sample size calculations; differences at baseline; diagnostic codes; no influenza-specific outcomes   [@cit0031]CanadaRetrospective cohort study2000-200853/74/74^l,^[^m^](#t1fn0012){ref-type="fn"}52/47/44[^m^](#t1fn0012){ref-type="fn"}70,380/50,308/76,233[^m^](#t1fn0012){ref-type="fn"}^,^[^n^](#t1fn0013){ref-type="fn"}Type 1 & 2[^i^](#t1fn0009){ref-type="fn"}+ Acceptable quality           + Unvaccinated diabetic control group           - No sample size calculations; retrospective design; no description of diabetes types; diagnostic codes; no information on influenza seasons   [@cit0028]USA Retrospective cohort study1996-1998≥65[^d^](#t1fn0004){ref-type="fn"} NR1996: 14,915Type 1 & 2[^i^](#t1fn0009){ref-type="fn"}+ Acceptable quality       1997: 21,991 - Differences at baseline; retrospective design; no description of diabetes types; diagnostic codes   [@cit0029]USA Case-control study1992-199872.9/73.7^l,^[^o^](#t1fn0014){ref-type="fn"} 32.2/34.7[^o^](#t1fn0014){ref-type="fn"}1,735/180[^o^](#t1fn0014){ref-type="fn"}Type 1 & 2^l^- Low quality         - No sample size calculations; differences at baseline; no description of diabetes types; diagnostic codes; no influenza-specific outcomes; no information on influenza seasons   [@cit0034]The Netherlands Retrospective cohort study1999-200058.6[^q^](#t1fn0016){ref-type="fn"} 1999: 491999: 2,944Type 1 & 2[^i^](#t1fn0009){ref-type="fn"}- Low quality     2001--2002[^p^](#t1fn0015){ref-type="fn"}  2001: 502001: 5,035 - No sample size calculations; retrospective design; no description of diabetes types; diagnostic codes; no influenza-specific outcomes; no information on matching *Effectiveness and cost-effectiveness*    [@cit0035]Taiwan Retrospective cohort study2001-200973.1 (5.9)/73.2 (6.8)50.0/49.54,571/4,454Type 1 & 2[^i^](#t1fn0009){ref-type="fn"}+ Acceptable quality          + Unvaccinated diabetic control group           - No sample size calculations; retrospective design; differences at baseline; no description of diabetes types; diagnostic codes; no information on influenza seasons   [^2][^3][^4][^5][^6][^7][^8][^9][^10][^11][^12][^13][^14][^15][^16][^17][^18][^19]

Immunogenicity {#s0003-0003}
--------------

Six studies provided data on the immunogenicity of seasonal influenza vaccination in diabetic patients (one randomized double-blind trial of acceptable quality, one randomized double-blind trial of low quality, three non-randomized clinical studies of low quality and one prospective cohort study of acceptable quality).[@cit0022] Four studies included a control group of healthy participants.[@cit0022] Two of these studies assessed immunogenicity by change in HI titers four weeks after vaccination; both found the immune response of diabetic patients to be comparable to that of healthy participants.[@cit0022]^,^[@cit0023] Immunogenicity was not found to decrease with age in patients with diabetes, when comparing results of adult patients (mean age of 50 years) with results of elderly patients (mean age of 64 years).[@cit0022] In a population of elderly patients (≥65 years old) good glycemic control was shown to be important to accurately measure immune response to seasonal influenza vaccination in this population.[@cit0023] However, the studies of Frasca et al. and McElhaney et al. might not be comparable in key characteristics of the study populations, such as control of the disease.

The four other studies presented SCR and/or SPR one month after vaccination ([Table 2](#t0002){ref-type="table"} and Figure 1S).[@cit0024] SCR ranged from 44.0--54.9% for the A/H1N1 strain, 27.7--58.0% for the A/H3N2 strain and 24.0--54.3% for the B strain. SCR were above the criterion for licensure (i.e. \>40%) for all vaccine strains in all studies, except for the A/H3N2 strain in one study[@cit0027] and for the B strain during a second influenza season in another study.[@cit0025] No significant differences in SCR at one-month post-vaccination for individual vaccine strains were seen between patients with diabetes and healthy participants in studies which included a control group, except against the B strain in one study (24.0% versus 31.9%, respectively; p = 0.05).[@cit0025] Two studies also measured SCR six months after vaccination.[@cit0024]^,^[@cit0027] At this timepoint, SCR for most vaccine strains were below the recommended thresholds ([Table 2](#t0002){ref-type="table"}). No significant differences in SCR at this timepoint were reported between patients with diabetes and healthy participants in the study which included a control group.[@cit0024] Table 2.Seroconversion and seroprotection rates one and six months after seasonal influenza vaccination in patients with diabetes.ReferenceCountryStudy designInfluenza seasonVaccine typeInfluenza type/subtypenPatient characteristicsImmunogenicity outcome % (n/N or 95% CI)**Seroconversion rate (1 month)**        [@cit0024] (SIGN -)KoreaNon-randomized clinical study2012-2013TIVA/H1N1105Type 2 / ≥19 years54.3% (57/105)     A/H3N2105 46.7% (49/105)     B105 54.3% (57/105)[@cit0025] (SIGN +)USAProspective cohort study2009-2010TIV  Type 2 / ≥18 years*Year 1*     A/H1N191 54.9% (NR)     A/H3N291 57.7% (NR)     B91 40.0% (NR)   2010--2011    *Year 2*     A/H1N1102 44.0% (NR)     A/H3N2102 58.0% (NR)     B102 24.0% (NR)[^\*^](#t2fn0001){ref-type="fn"}[@cit0027] (SIGN +)ItalyRandomized, double-blind trial2007-2008SubunitA/H1N153Type 1 / 9--30 years44.7% (30.2--59.9)     A/H3N253 27.7% (15.6--42.6)[^\*^](#t2fn0001){ref-type="fn"}     B53 42.6% (28.3--57.8)    Virosomal         A/H1N152 50.0% (35.2--64.8)     A/H3N252 31.2% (18.7--46.2)[^\*^](#t2fn0001){ref-type="fn"}     B52 50.0% (35.2--64.8)**Seroconversion rate (6 months)**        [@cit0024] (SIGN −)KoreaNon-randomized clinical study2012--2013TIVA/H1N1105Type 2 / ≥19 years26.7% (28/105)[^\*^](#t2fn0001){ref-type="fn"}     A/H3N2105 34.3% (36/105)[^\*^](#t2fn0001){ref-type="fn"}     B105 32.4% (34/105)[^\*^](#t2fn0001){ref-type="fn"}[@cit0027] (SIGN +)ItalyRandomized, double-blind trial2007--2008SubunitA/H1N153Type 1 / 9--30 years42.6% (28.3--57.8)     A/H3N253 14.9% (6.2--28.3)[^\*^](#t2fn0001){ref-type="fn"}     B53 25.5% (13.9--40.3)[^\*^](#t2fn0001){ref-type="fn"}    VirosomalA/H1N152 41.7% (27.6--56.8)     A/H3N252 20.8% (10.5--35.0)[^\*^](#t2fn0001){ref-type="fn"}     B52 45.8% (31.4--60.8)**Seroprotection rate (1 month)**        [@cit0024] (SIGN -)KoreaNon-randomized clinical study2012-2013TIVA/H1N1105Type 2 / ≥19 years69.5% (73/105)[^\*^](#t2fn0001){ref-type="fn"}     A/H3N2105 99.0% (104/105)     B105 56.2% (59/105)[^\*^](#t2fn0001){ref-type="fn"}[@cit0025] (SIGN +)USAProspective cohort study2009-2010TIV  Type 2 / ≥65 years*Year 1*     A/H1N191 76.1% (NR)     A/H3N291 85.9% (NR)     B91 42.3% (NR)[^\*^](#t2fn0001){ref-type="fn"}   2010--2011TIV  Type 2 / ≥65 years*Year 2*     A/H1N1102 46.0% (NR)[^\*^](#t2fn0001){ref-type="fn"}     A/H3N2102 77.0% (NR)     B102 29.0% (NR)[^\*^](#t2fn0001){ref-type="fn"}[@cit0026] (SIGN -)USARandomized, double-blind trial2008-2010TIV  Type 1 / 7--35 years*Year 1*     A/H1N129 89.7% (NR)     A/H3N229 93.1% (NR)     B29 72.4% (NR)        *Year 2*     A/H1N116 87.5% (NR)     A/H3N216 93.8% (NR)     B16 43.8%[^\*^](#t2fn0001){ref-type="fn"} (NR)[@cit0027] (SIGN +)ItalyRandomized, double-blind trial2007-2008SubunitA/H1N153Type 1 / 9--30 years100% (92.4-100)     A/H3N253 95.7% (85.5-99.5)     B53 70.2% (55.1-82.7)    VirosomalA/H1N152 100% (92.6-100)     A/H3N252 100% (92.6-100)     B52 72.9% (58.1-84.7)**Seroprotection rate (6 months)**        [@cit0024] (SIGN -)KoreaNon-randomized clinical study2012-2013TIVA/H1N1105Type 2 / ≥19 years43.8% (46/105)[^\*^](#t2fn0001){ref-type="fn"}     A/H3N2105 95.2% (100/105)     B105 31.4% (33/105)[^\*^](#t2fn0001){ref-type="fn"}[@cit0027] (SIGN +)ItalyRandomized, double-blind trial2007-2008SubunitA/H1N153Type 1 / 9--30 years93.6% (82.5--98.7)     A/H3N253 95.7% (85.5--99.5)     B53 46.8% (32.1--61.9)[^\*^](#t2fn0001){ref-type="fn"}    VirosomalA/H1N152 91.7% (80.0--97.7)     A/H3N252 95.8% (85.7--99.5)     B52 62.5% (47.3--76.0)[^\*^](#t2fn0001){ref-type="fn"}[^20][^21]

SPR one month after vaccination ranged from 46.0--100% for the A/H1N1 strain, 77.0--100% for the A/H3N2 strain and 29.0--72.9% for the B strain (see [Table 2](#t0002){ref-type="table"} and Figure 2S).[@cit0024] SPR for the A/H1N1 and A/H3N2 strains were generally above the criterion for licensure (i.e. \>70%); however, SPR for the B strain tended to be lower. No significant differences in SPR for individual vaccine strains were seen between patients with diabetes and healthy participants in studies which included a control group, except for the B strain during a second influenza season in one study (29.0% versus 40.7%, respectively; p = 0.04).[@cit0025] SPR six months after seasonal influenza vaccination generally remained high for the A/H1N1 and A/H3N2 strains, but decreased compared with the rates initially observed one month after vaccination.[@cit0024]^,^[@cit0027] No significant differences in SPR for the A/H3N2 and B strains at this timepoint were seen between patients with diabetes and healthy participants in the study which included a control group; however, the SPR for the A/H1N1 strain was significantly lower in patients with diabetes (43.8% versus 59.3% in healthy participants; p = 0.028).[@cit0024]

Effectiveness {#s0003-0004}
-------------

Nine studies (two case-control studies \[one of acceptable quality and one of low quality\] and seven retrospective cohort studies \[four of acceptable quality and three of low quality\]) provided data on seasonal influenza vaccine effectiveness in patients with diabetes.[@cit0028]

Five studies reported the effect of seasonal influenza vaccination on all-cause mortality in patients with diabetes ([Table 3](#t0003){ref-type="table"}).[@cit0030]^,^[@cit0032]^,^[@cit0033]^,^[@cit0035]^,^[@cit0036] All found seasonal influenza vaccination to be effective in preventing mortality in diabetic patients, particularly those aged ≥65 years. Vamos et al.[@cit0036] found that seasonal influenza vaccination was associated with a 50% reduction in all-cause mortality during influenza seasons over the 7-year study period in adult patients with type 2 diabetes (incidence rate ratio \[IRR\], 0.50 \[95% CI 0.45-0.54\]; *p* ≤ 0.001). Excluding the 2008/09 cohort (preceding the pandemic when the A/H1N1~pdm09~ influenza strain was circulating) from the analysis did not impact the IRR obtained. In the study by Wang et al.,[@cit0035] the hazard ratio for all-cause mortality was 0.40 (95% CI 0.29-0.56) in patients aged 65--74 years and 0.46 (95% CI 0.35-0.59) in those aged ≥75 years who received influenza vaccination as compared to non-vaccinated. In the study reported by Rodriguez-Blanco et al.,[@cit0033] a multivariate adjusted analysis combining results of four influenza seasons (2002-2005) produced an odds ratio (OR) for all-cause mortality of 0.67 (95% CI 0.47-0.96) in diabetic patients aged ≥65 years who received influenza vaccination. Heymann et al.[@cit0030] reported that the ORs of death for elderly male and female patients were 0.35 (95% CI 0.25-0.49) and 0.32 (95% CI 0.20-0.50), respectively. Looijman-Van den Akker et al.[@cit0032] reported that vaccine effectiveness for the prevention of all-cause mortality during influenza season was 56% (95% CI 4%-80%) in diabetic patients aged ≥65 years compared with 24% (95% CI -706%-93%) in those aged 18--64 years. Table 3.Effectiveness of seasonal influenza vaccination for the prevention of mortality and hospitalization in patients with diabetes.ReferenceCountryStudy designInfluenza seasonnDiabetes typeSubgroup analysisEffectiveness outcome       Mortality[@cit0036] (SIGN +)UKRetrospective cohort study2003-2010107,598.2 PYType 2 *IRR (95% CI) all-cause mortality*       0.50 (0.45-0.54) \[0.52 (0.47-0.58)\][^a^](#t3fn0001){ref-type="fn"}[@cit0035] (SIGN +)TaiwanRetrospective cohort study2001-2009 Type 1 & 2 *IRR (95% CI) all-cause mortality*    5,954 65--74 years0.40 (0.34-0.47)    3,071 ≥75 years0.41 (0.34-0.50)       *HR (95% CI) all-cause mortality*    5,954 65--74 years0.40 (0.29-0.56)    3,071 ≥75 years0.46 (0.35-0.59)[@cit0033] (SIGN -)SpainRetrospective cohort study20021,586Type 1 & 2≥65 years*Incidence (95% CI) all-cause mortality per 1,000 person-influenza period*    1,064 Vaccinated7.6 (3.9-13.2)      Unvaccinated11.3 (5.9-19.7)   20031,682 Vaccinated16.7 (11.2-24.2)    876 Unvaccinated21.7 (13.3-34.1)   20041,715 Vaccinated14.6 (9.5-21.6)    707 Unvaccinated18.4 (9.9-31.5)   20051,629 Vaccinated25.2 (18.2-34.8)    657 Unvaccinated25.9 (15.1-42.1)      Overall*RRR (95% CI) all-cause mortality*   20022,650  0.67 (0.29-1.48)   20032,558  0.77 (0.43-1.39)   20042,422  0.79 (0.41-1.56)   20052,286  0.97 (0.48-1.82)   2002--20059,916 Overall*Multivariate adjusted OR (95% CI) all-cause mortality*       0.67 (0.47--0.96)[@cit0030] (SIGN -)IsraelRetrospective cohort study2000-2001 Type 1 & 2*MenOR (95% CI) all-cause mortality*    5,195 65--75 years0.37 (0.21--0.66)    2,278 \>75-85 years0.36 (0.22--0.58)    456 \>85 years0.28 (0.12--0.64)    7,929 Overall0.35 (0.25--0.49)      *WomenOR (95% CI) all-cause mortality*    5,215 65--75 years0.39 (0.21--0.73)    2,713 \>75-85 years0.09 (0.03-0.24)    526 \>85 years0.57 (0.24--1.33)    8,454 Overall0.32 (0.20--0.50)[@cit0032] (SIGN +)The NetherlandsNested case-control study1999-2000439\>90% Type 2*18-64 yearsIR all-cause mortality*      Vaccinated2.0      Unvaccinated3.1    1,314 *≥65 yearsIR all-cause mortality*      Vaccinated8.4      Unvaccinated18.7    1,753 ≥18 years*Adjusted VE (95% CI)*       58% (13-80)    439 18--64 years24% (-706-93)    1,314 ≥65 years56% (4-80)       Hospitalisation[@cit0036] (SIGN +)UKRetrospective cohort study2003-2010108,231.6 PYType 2 *IRR (95% CI) hospitalization for myocardial infarction*       0.78 (0.65-0.93) \[0.76 (0.62-0.93)\][^a^](#t3fn0001){ref-type="fn"}    108,282.8 PY  *IRR (95% CI) hospitalization for stroke*       0.82 (0.67-1.00) \[0.86 (0.69-1.07)\]    107,700.7 PY  *IRR (95% CI) hospitalization for heart failure*       0.83 (0.74-0.93) \[0.82 (0.72-0.93)\]    107,657.9 PY  *IRR (95% CI) hospitalization for pneumonia/influenza*       0.75 (0.68-0.82) \[0.76 (0.68-0.85)\][@cit0035] (SIGN +)TaiwanRetrospective cohort study2001-2009 Type 1 & 2 *IRR (95% CI) any hospitalization*    5,954 65--74 years0.96 (0.86-1.09)    3,071 ≥75 years0.84 (0.72-0.98)       *IRR (95% CI) hospitalization for pneumonia/influenza*      65--74 years0.98 (0.86-1.12)      ≥75 years0.77 (0.65-0.92)       *IRR (95% CI) hospitalization for respiratory failure*      65--74 years0.98 (0.83-1.16)      ≥75 years0.50 (0.41-0.62)       *IRR (95% CI) intensive care unit*      65--74 years0.37 (0.30-0.45)      ≥75 years0.25 (0.19-0.33)       *HR (95% CI) any hospitalization*    5,954 65--74 years0.91 (0.81-1.02)    3,071 ≥75 years0.85 (0.75-0.96)       *HR (95% CI) hospitalization for pneumonia/influenza*      65--74 years0.93 (0.80-1.09)      ≥75 years0.78 (0.65-0.93)       *HR (95% CI) hospitalization for respiratory failure*      65--74 years0.97 (0.63-1.49)      ≥75 years0.55 (0.40-0.76)       *HR (95% CI) intensive care unit*      65--74 years0.40 (0.29-0.56)      ≥75 years0.46 (0.35-0.59)[@cit0030] (SIGN -)IsraelRetrospective cohort study2000-2001 Type 1 & 2*MenOR (95% CI) hospitalization*      65--75 years0.99 (0.81-1.22)      75--85 years0.80 (0.62-1.05)      \>85 years0.48 (0.25-0.95)      *WomenOR (95% CI) hospitalizations*      65--75 years0.85 (0.68-1.04)      75--85 years0.79 (0.61-1.02)      \>85 years0.92 (0.51-1.66)[@cit0032] (SIGN +)The NetherlandsNested case-control study1999-2000439\>90% Type 2*18-64 yearsIR hospitalization*      Vaccinated12.0      Unvaccinated25.2    1,314 *≥65 yearsIR hospitalization*      Vaccinated13.9      Unvaccinated11.2       *Adjusted VE (95% CI) against hospitalization*    1,753 ≥18 years54% (26-71)    439 18--64 years70% (39-85)    1,314 ≥65 years14% (-88-60)[@cit0031] (SIGN +)CanadaRetrospective cohort study2000-2008 Type 1 & 2 *IRR (95% CI) all hospitalizations*    70380 PY 18--64 years0.72 (0.68-0.76)    50308 PY ≥65 years0.67 (0.64-0.70)       *IRR (95% CI) hospitalization for pneumonia*    70380 PY 18--64 years0.57 (0.46-0.72)    50308 PY ≥65 years0.55 (0.47-0.66)       *IRR (95% CI) hospitalization for influenza-like illness*    70380 PY 18--64 years0.99 (0.97-1.01)    50308 PY ≥75 years0.87 (0.84-0.90)[^22][^23][^24]

Five studies provided data on the effect of seasonal influenza vaccination on the risk of hospitalization in patients with diabetes mellitus ([Table 3](#t0003){ref-type="table"}).[@cit0030]^,^[@cit0031]^,^[@cit0032]^,^[@cit0035]^,^[@cit0036] Seasonal influenza vaccination was associated with significantly lower admission rates for acute myocardial infarction (MI) (IRR, 0.78 \[95% CI 0.65-0.93\]; *p* ≤ 0.01), heart failure (IRR, 0.83 \[95% CI 0.74-0.93\]; *p* ≤ 0.001) and pneumonia/influenza (IRR, 0.75 \[95% CI 0.68-0.82\]; *p* ≤ 0.001) and a reduction (although not statistically significant) in hospital admissions for stroke (IRR, 0.82 \[95% CI 0.67-1.00\]), during influenza seasons over a 7-year study period in adult patients with type 2 diabetes.[@cit0036] Seasonal influenza vaccination was effective for the prevention of hospitalization for pneumonia or influenza in diabetic patients aged 18--64 years, ≥65 years and ≥75 years in two studies,[@cit0031]^,^[@cit0035] as well as for the prevention of hospitalization for respiratory failure in diabetic patients aged ≥75 years and intensive care unit admission in those aged ≥65 years in one of these studies.[@cit0035] In another study, seasonal influenza vaccine was effective for the prevention of hospitalization in diabetic patients aged 18--64 years, but not in those aged ≥65 years. (Looijmans-Van et al.[@cit0032] Vaccine effectiveness for the prevention of hospitalizations due to influenza, pneumonia, other acute respiratory disease, MI, congestive heart failure, stroke or diabetes was 70% (95% CI 39--85%) in patients aged 18--64 years compared to 14% (95% CI -88-60%) in those aged ≥65 years. This difference might be explained by differences in key characteristics of the younger and older patients. Elderly patients experience senescence or biological ageing (i.e. which refers to the gradual decline of functions' characteristics linked specifically to cells or to the whole organism).[@cit0032] In another study, deemed low quality, seasonal influenza vaccination was only effective for the prevention of hospitalization in internal medicine and geriatric wards for male patients aged \>85 years, but not in male patients in other age groups or females.[@cit0030]

In another study, seasonal influenza vaccination was found to be effective in reducing the risk of hospitalization for pneumonia or influenza and mortality from all causes in elderly patients with diabetes over two influenza seasons.[@cit0028] Vaccine effectiveness was 50% (95% CI 37--60%) in the first year and 21% (95% CI 6--34%) in the second year in diabetic patients compared with 46% (95% CI 34--56%) and 42% (95% CI 25--52%) in the two years, respectively, in healthy elderly participants.

Three studies provided data on effectiveness outcomes other than mortality or hospitalization.[@cit0029]^,^[@cit0031]^,^[@cit0034] In one study, a significant association was found between seasonal influenza vaccination and the incidence of influenza-like illness in diabetic patients aged ≥65 years, but no association was found in patients aged 18--64 years.[@cit0031] In a second study conducted over two influenza seasons, no difference in the number of general practitioner (GP) visits was found between vaccinated and unvaccinated patients with diabetes during a mild season; however, in a more virulent influenza season, vaccinated patients visited the GP less often than unvaccinated patients.[@cit0034] In the third study, the association between influenza vaccination and risk of incident MI in persons at least 65 years of age with and without diabetes was analyzed. This study does not provide evidence supporting an association of influenza vaccination and reduction in risk of MI.[@cit0029]

Cost effectiveness {#s0003-0005}
------------------

One study of acceptable quality reported that seasonal influenza vaccination reduced the cost of hospitalization in patients with diabetes by US\$1283 (95% CI -2210, -355) compared with unvaccinated diabetic patients.[@cit0035]

Safety {#s0003-0006}
------

Two studies provided data on the reactogenicity and/or safety of seasonal influenza vaccination in diabetic patients.[@cit0024]^,^[@cit0027] In a randomized controlled trial of acceptable quality which compared the reactogenicity of a trivalent inactivated vaccine with a virosomal vaccine in children with type 1 diabetes, only transient and non-severe adverse reactions were reported in both groups.[@cit0027] A non-randomized clinical study of low quality compared adverse events following seasonal influenza vaccination in patients with type 2 diabetes with those in healthy participants.[@cit0024] All local reactions (i.e. injection-site pain, tenderness, redness and swelling) were less frequently reported by diabetic individuals than by nondiabetics, although systemic reactions (i.e. headache, malaise, chills, tiredness, sweating, myalgia and arthralgia) were reported at similar rates in the two groups.

Discussion {#s0004}
==========

This comprehensive systematic literature review was undertaken to critically assess currently available data on the immunogenicity, safety, efficacy, effectiveness, quality of life and cost effectiveness of seasonal influenza vaccination in diabetic patients. Although some evidence is missing and limited for some endpoints, the overall findings consistently support the benefit of seasonal influenza vaccination in this population. In addition, in most of the identified studies, the immunogenicity of seasonal influenza vaccination in diabetic patients was found to be comparable to that in healthy participants or non-diabetic participants.[@cit0022] SCR and SPR one month after vaccination were generally above the recommended criteria for licensure (\>40% and \>70, respectively), with however some variation in SCR and SPR seen across studies most likely reflecting differences in the degree of similarity between the vaccine strains and predominant circulating strains during study periods. In terms of safety, seasonal influenza vaccination was found to be well-tolerated in both children with type 1 diabetes and in adults with type 2 diabetes,[@cit0024]^,^[@cit0027] which is aligned with the known safety profile of seasonal influenza vaccines in healthy adults.[@cit0037] During the selection phase, the study of[@cit0038] was identified, it did not fit the inclusion criteria.[@cit0038] This small study compared the antibody response to A/H3N2 for adults with type 2 diabetes versus non-diabetic subjects and did not find differences between these two populations in the immune response measured.

Seasonal influenza vaccination was found to be associated with a significantly reduced risk of all-cause mortality in diabetic patients, particularly older adults aged ≥65 years. Previous systematic reviews highlighted lack of adjustment for residual confounding as a major limitation of most studies of the effectiveness of influenza vaccination in diabetic patients.[@cit0013]^,^[@cit0014]

In the largest study included in this systematic review, published more recently --- a retrospective cohort study involving 125,503 adults with type 2 diabetes --- all-cause mortality was 24% lower during the influenza season in vaccine recipients as compared with unvaccinated participants after adjustment for residual confounding (IRR 0.76, 95% CI 0.65-0.83).[@cit0036]

Seasonal influenza vaccination was also found to be associated with significant reductions in the risk of hospitalization in diabetic patients in most studies included in the current systematic review. After adjustment for residual confounding in the large retrospective cohort study of adult patients with type 2 diabetes (n = 124,503), vaccination was associated with a 22% reduction during the influenza season in the rate of hospital admissions for acute MI (IRR 0.78, 95% CI 0.65-0.93), 18% for stroke (IRR 0.82, 95% CI 0.67-1.00), 17% for heart failure (IRR 0.83, 95% 0.74-0.93) and 25% for pneumonia or influenza (IRR 0.75, 95% CI 0.68-0.82).[@cit0036] Cost-effectiveness data were sparse; however, one study conducted on universal claims data from 2001 and 2009 and encompassing almost 9,000 diabetic patients found hospitalization costs to be significantly lower in vaccinated diabetic patients than in unvaccinated patients with diabetes.[@cit0035]

A major strength of this systematic review is that it provides data on a wider range of clinically relevant outcomes than previous analyses.[@cit0013]^,^[@cit0014] This literature review attempts to present and appraise several components including clinical trials, observational studies and cost-effectiveness studies. For example, immunogenicity data were also included in the present review to give a more complete overview of the available data on seasonal influenza vaccination in patients with diabetes. This is an important addition because healthcare professionals might be reluctant to vaccinate diabetic patients or patients themselves to receive the vaccination if they are not fully aware of the associated risks in case of infections or do not fully know the benefit of seasonal vaccination. An additional strength is the inclusion of studies which only considered a population of diabetic patients (or separate analysis of the diabetic patient group) allowing for a targeted assessment of the available evidence; this is important as patients with different medical conditions might vary in their response to the vaccine.

This review encompasses some limitations. The paucity of data available for some outcomes; such as the safety or the cost-effectiveness component which limits the possibility to have an overview of the safety profiles or to consistently measure the financial impact of the vaccination in this risk group; only two studies reported safety data[@cit0024]^,^[@cit0027] and a single study provided cost-effectiveness data.[@cit0035] No studies providing data on vaccine efficacy or quality of life were identified. Furthermore, the included studies were heterogeneous in terms of the considered populations (age groups, diabetes type, healthcare setting), settings, influenza seasons covered, outcomes and the outcome measures used, making it difficult to compare findings between studies. Another limitation is the fact that the included studies were conducted during different influenza seasons from 1992--2013. Influenza seasons vary in length and severity, which may lead to differences in findings unrelated to the population studied. Every season, the influenza vaccine is potentially re-formulated based on WHO recommendations as influenza viruses evolve continuously. The degree to which the strains included in the vaccine match the circulating strains has a large impact on the effectiveness of the vaccine during a season.[@cit0039] In this review, it was not possible to control for this by segregating results according to the degree of matching between strains included in the vaccine and circulating strains due to the relatively low number of included studies. On the other hand, this work provides a picture of more than 10 years of a consistent trend supporting the value of seasonal influenza vaccination in patients with diabetes mellitus. In addition, no limits were set on sample size during study selection, meaning some relatively underpowered studies were included. The smallest was a non-randomized clinical study in which data were stratified on age and the sample of elderly diabetic patients involved eight participants,[@cit0022] while the largest was a retrospective 7-year cohort study of 124,503 adults with type 2 diabetes.[@cit0036]

No high-quality randomized controlled trials of seasonal influenza vaccination in diabetic patients were identified for inclusion in this review. Of the included studies, seven were considered to be of acceptable quality and eight were considered to be of lower quality. Potential sources of bias were identified in many studies, including lack of sample size calculations, significant differences in patient and clinical characteristics between study groups at baseline, variability in application of diagnostic codes, lack of influenza-specific outcomes and retrospective design. Selection bias may be a limitation of the included observational studies, which might result in large differences in baseline characteristics between vaccinated and unvaccinated patients. For example, vaccine uptake may be higher in patients with more severe diseases as they might be more likely to recognize the value of vaccination and their doctors might be more incline to encourage influenza vaccination. In contrast, in vaccine studies the healthy vaccinee effect cannot be excluded, assuming that a patient who adopts healthy behaviors may be more likely to receive the vaccine and/or might be more prone to also seek other preventive measures and therefore may have better outcomes than unvaccinated and less health-conscious counterparts[@cit0040]; this effect being more likely to occur in the broad population, rather than in a vulnerable group recommended for annual vaccination. Measures for accounting for potential differences at baseline are crucial during statistical analysis; nevertheless, residual confounding cannot be completely ruled out in observational studies.

In conclusion, this systematic literature review brought additional inputs and provides significant evidence of the value of seasonal influenza vaccination in diabetic patients, particularly for the prevention of severe disease complications. These findings consistently support existing recommendations for seasonal influenza vaccination in this vulnerable patient population.

Supplementary Material
======================

###### KHVI_A\_1446719_Supplemental.docx

Disclosure of potential conflicts of interest
=============================================

Gael Dos Santos, Halima Tahrat and Rafik Bekkat-Berkani are employed by the GSK group of companies and hold shares in the GSK group of companies. GSK is a manufacturer of commercial influenza vaccines.

Acknowledgments
===============

The authors thank Anar Andani, Anne Schuind, Emad Yanni and Selim Badur for their critical review of the manuscript. The authors also thank Anouk Oordt and Jennifer Eeuwijk (Pallas, Health Research and Consultancy, Rotterdam, The Netherlands) for their contribution to the design of the literature review, data collection, for having performed the analysis, and for writing assistance; Mary L Greenacre (An Sgriobhadair, UK, on behalf of GSK) for writing assistance; and Business & Decision Life Sciences platform (on behalf of GSK) for editorial assistance and manuscript coordination. Bruno Dumont coordinated the manuscript development and provided editorial support.

Author contributions
====================

All authors participated in the design and/or interpretation of the systematic review. The systematic review was performed by Pallas, Health Research and Consultancy, Rotterdam, The Netherlands. All authors had full access to the data, contributed to the development of this manuscript and gave final approval before submission.

[^1]: Supplemental data for this article can be accessed on the [publisher\'s website](https://doi.org/10.1080/21645515.2018.1446719).

[^2]: n: number of participants; NR: not reported; RCT: randomized controlled trial; SD: standard deviation; UK: United Kingdom; USA: United States of America

[^3]: Age and gender presented as vaccinated/unvaccinated or diabetics/non-diabetics where available;

[^4]: Young (20--59 years), Elderly (\>60 years);

[^5]: Only one season per subject;

[^6]: Mean age not reported;

[^7]: For the total study population;

[^8]: *Subunit/virosomal vaccine*;

[^9]: In season 2003/2004;

[^10]: Total number of patients enrolled, including a total of 623,591 Person-Years;

[^11]: No data on the proportion of patients with type 1 or type 2 diabetes;

[^12]: Vaccinated vs unvaccinated patients with diabetes and vaccinated vs unvaccinated in subjects without diabetes;

[^13]: Case participants vs controls;

[^14]: ^l^ Median age;

[^15]: Working-age diabetic participants, elderly diabetic participants and elderly without diabetes;

[^16]: Included person-years; Data were collected annually;

[^17]: Controls vs myocardial infarction cases;

[^18]: In 2000--2001, no epidemic occurred and therefore no data were collected;

[^19]: In high risk groups, no mean age of patients with diabetes available.

[^20]: CI: confidence interval; N: number; n/N: subgroup/total study population; NR: not reported; TIV: trivalent inactivated vaccine; USA: United States of America.

[^21]: According to immunogenicity criteria for licensure: seroconversion rate should be \>40% and seroprotection rate should be \>70% in adults 18--60 years, seroconversion rate should be \>30% and seroprotection rate should be \>60% in adults \>60 years.

[^22]: CI: confidence interval; HR, hazard ratio; IR, incidence rate; IRR, incidence rate ratio; n: number; OR, odds ratio; PY, person-years; RRR, relative risk ratio; UK: United Kingdom; VE: vaccine effectiveness.

[^23]: Excluding 2008/2009 when the outbreak of pandemic A/H1N1~pdm09~ occurred;

[^24]: Hospitalizations for physician-diagnosed influenza, pneumonia, other acute respiratory disease, myocardial infarction, heart failure, stroke or diabetes dysregulation.
